AQST Aquestive Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: AQST

Price (delayed)

$4.25

Market cap

$533.42M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.66

Enterprise value

$583.97M

?
Relative Growth: Rel. Growth: 28
Relative Strength: Rel. Strength: 38
Relative Valuation: Rel. Valuation: 9
Relative Profitability: Rel. Profitability: 19

Aquestive is pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies. We are developing orally administered products to deliver complex molecules, providing ...

Highlights
Aquestive Therapeutics's quick ratio has surged by 109% YoY and by 77% QoQ
The company's gross profit rose by 34% YoY and by 14% QoQ
AQST's equity has dropped by 66% since the previous quarter but it is up by 22% year-on-year
The EPS has declined by 6% since the previous quarter but it has grown by 6% year-on-year
AQST's net income is down by 20% year-on-year and by 14% since the previous quarter
The debt has grown by 18% YoY and by 12% from the previous quarter
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.aquestive.com
Peers: OPK ORGO

Key stats

What are the main financial stats of AQST

AQST stock price

How has the Aquestive Therapeutics stock price performed over time
Intraday
0.47%
1 week
8.42%
1 month
4.68%
1 year
5.99%
YTD
-34.21%
QTD
2.16%

Financial performance

How have Aquestive Therapeutics's revenue and profit performed over time
Revenue
$54.09M
Gross profit
$36.26M
Operating income
-$52.75M
Net income
-$78.23M
Gross margin
67%
Net margin
-144.6%
The company's gross profit rose by 34% YoY and by 14% QoQ
Aquestive Therapeutics's revenue has increased by 23% YoY and by 8% from the previous quarter
AQST's net income is down by 20% year-on-year and by 14% since the previous quarter
Aquestive Therapeutics's operating margin has increased by 18% YoY and by 12% QoQ

Price vs fundamentals

How does AQST's price correlate with its fundamentals

Growth

What is Aquestive Therapeutics's growth rate over time

Valuation

What is Aquestive Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
9.82
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.8
The EPS has declined by 6% since the previous quarter but it has grown by 6% year-on-year
AQST's equity has dropped by 66% since the previous quarter but it is up by 22% year-on-year
AQST's P/S is 89% above its 5-year quarterly average of 5.2 but 21% below its last 4 quarters average of 12.4
Aquestive Therapeutics's revenue has increased by 23% YoY and by 8% from the previous quarter

Efficiency

How efficient is Aquestive Therapeutics business performance
The company's return on invested capital fell by 25% YoY and by 12% QoQ
AQST's ROA is up by 18% year-on-year but it is down by 6% since the previous quarter
The return on sales has declined by 10% since the previous quarter and by 5% year-on-year

Dividends

What is AQST's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AQST.

Financial health

How did Aquestive Therapeutics financials performed over time
The company's total assets is 30% lower than its total liabilities
Aquestive Therapeutics's quick ratio has surged by 109% YoY and by 77% QoQ
The current ratio has surged by 104% year-on-year and by 75% since the previous quarter
AQST's equity has dropped by 66% since the previous quarter but it is up by 22% year-on-year
AQST's debt to equity has dropped by 52% year-on-year but it is up by 33% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.